肾素-血管紧张素系统抑制剂继续与停用对大型手术后结局的影响:多中心随机对照试验(STOP-or-NOT试验)方案
本研究为多中心、开放标签随机对照试验,在法国超过30个中心开展,计划纳入2222例患者,旨在评估大型非心脏手术前继续与停用肾素-血管紧张素系统抑制剂(RASi)对围手术期并发症的影响。试验组继续使用RASi,对照组术前48小时停用,主要终点为术后主要并发症复合终点,主要分析采用意向性治疗比较两组28天时复合结局。
要点
- 多中心开放标签随机对照试验,计划纳入2222例,检验5%的绝对并发症差异。
- 试验组继续RASi,对照组术前48小时停用,主要终点为术后主要并发症复合终点。
- 主要分析为意向性治疗,比较两组28天时复合结局。
核心结论
- 该试验结果应能为麻醉科医生和外科医生关于大型非心脏手术前RASi的管理提供可靠证据。
研究设计与样本
- 多中心、开放标签随机对照试验,在法国超过30个中心开展,计划纳入2222例患者。
- 试验组继续使用RASi,对照组术前48小时停用。
- 主要终点为术后主要并发症复合终点,主要分析为意向性治疗,比较两组28天时复合结局。
- 设终点裁定委员会,在不知晓分组的情况下审核临床数据并裁定疗效终点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic treatment of hypertension or heart failure very often includes an angiotensin-converting enzyme inhibitors (ACE-Is) or angiotensin receptor blockers (ARBs) as renin-angiotensin system inhibitors (RASi) treatments. To stop or not to stop these medications before major surgery remains an unresolved issue. The lack of evidence leads to conflicting guidelines with respect to RASi management before major surgery. The purpose of this study is to evaluate the impact of a strategy of RASi continuation or discontinuation on perioperative complications in patients undergoing major non-cardiac surgery. METHODS: This is a multicenter, open-labeled randomized controlled trial in > 30 French centers. In the experimental group, RASi will be continued while the treatment will be stopped 48 h before the surgery in the control arm. The primary endpoint is a composite endpoint of major complications after surgery. An endpoint adjudication committee will review clinical data and adjudicate efficacy endpoints while blinded to the assigned study drug group. Main analysis will be by intention-to-treat comparing the composite outcome measure at 28 days in the two groups. A total of 2222 patients are planned to detect an absolute complications difference of 5%. DISCUSSION: The results of the trial should provide robust evidence to anesthesiologists and surgeons regarding management of RASi before major non-cardiac surgery. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03374449 . Registered on 11 December 2017.
引用
- Legrand M, Futier E, Leone M, et al. Impact of renin-angiotensin system inhibitors continuation versus discontinuation on outcome after major surgery: protocol of a multicenter randomized, controlled trial (STOP-or-NOT trial). Trials. 2019. PMID: 30836981. doi:10.1186/s13063-019-3247-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。